Core Unit Proteomics, Institute of Toxicology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.
Division of Paediatric Neurology, University of Basel Children's Hospital, Basel, Switzerland.
Amino Acids. 2018 Oct;50(10):1391-1406. doi: 10.1007/s00726-018-2614-7. Epub 2018 Jul 12.
The L-arginine/nitric oxide synthase (NOS) pathway is considered to be altered in muscular dystrophy such as Becker muscular dystrophy (BMD). We investigated two pharmacological options aimed to increase nitric oxide (NO) synthesis in 20 male BMD patients (age range 21-44 years): (1) supplementation with L-citrulline (3 × 5 g/d), the precursor of L-arginine which is the substrate of neuronal NO synthase (nNOS); and (2) treatment with the antidiabetic drug metformin (3 × 500 mg/d) which activates nNOS in human skeletal muscle. We also investigated the combined use of L-citrulline (3 × 5 g/d) and metformin (3 × 500 mg/d). Before and after treatment, we measured in serum and urine samples the concentration of amino acids and metabolites of L-arginine-related pathways and the oxidative stress biomarker malondialdehyde (MDA). Compared to healthy subjects, BMD patients have altered NOS, arginine:glycine amidinotransferase (AGAT) and guanidinoacetate methyltransferase (GAMT) pathways. Metformin treatment resulted in concentration decrease of arginine and MDA in serum, and of homoarginine (hArg) and guanidinoacetate (GAA) in serum and urine. L-Citrulline supplementation resulted in considerable increase of the concentrations of amino acids and creatinine in the serum, and in their urinary excretion rates. Combined use of metformin and L-citrulline attenuated the effects obtained from their single administrations. Metformin, L-citrulline or their combination did not alter serum nitrite and nitrate concentrations and their urinary excretion rates. In conclusion, metformin or L-citrulline supplementation to BMD patients results in remarkable antidromic changes of the AGAT and GAMT pathways. In combination, metformin and L-citrulline at the doses used in the present study seem to abolish the biochemical effects of the single drugs in slight favor of L-citrulline.
精氨酸/一氧化氮合酶(NOS)途径被认为在肌营养不良症(如贝克肌营养不良症(BMD))中发生改变。我们研究了两种旨在增加一氧化氮(NO)合成的药理学选择,这两种选择适用于 20 名男性 BMD 患者(年龄范围 21-44 岁):(1)补充 L-瓜氨酸(3×5 g/d),L-瓜氨酸是 L-精氨酸的前体,而 L-精氨酸是神经元 NOS(nNOS)的底物;(2)用抗糖尿病药物二甲双胍(3×500 mg/d)治疗,该药物可激活人骨骼肌中的 nNOS。我们还研究了 L-瓜氨酸(3×5 g/d)和二甲双胍(3×500 mg/d)的联合使用。在治疗前后,我们测量了血清和尿液样本中氨基酸和 L-精氨酸相关途径代谢产物以及氧化应激生物标志物丙二醛(MDA)的浓度。与健康受试者相比,BMD 患者的 NOS、精氨酸:甘氨酸酰胺转移酶(AGAT)和胍基乙酸甲基转移酶(GAMT)途径发生改变。二甲双胍治疗导致血清中精氨酸和 MDA 以及血清和尿液中同型精氨酸(hArg)和胍基乙酸(GAA)的浓度降低。L-瓜氨酸补充导致血清中氨基酸和肌酐的浓度以及其尿排泄率显著增加。二甲双胍和 L-瓜氨酸联合使用减弱了它们单独给药的效果。二甲双胍、L-瓜氨酸或它们的组合并未改变血清中亚硝酸盐和硝酸盐的浓度及其尿排泄率。总之,二甲双胍或 L-瓜氨酸补充到 BMD 患者中会导致 AGAT 和 GAMT 途径发生显著的逆行变化。联合使用时,本研究中使用的剂量的二甲双胍和 L-瓜氨酸似乎消除了单一药物的生化作用,略微有利于 L-瓜氨酸。